SCHEMBL20203510

SCHEMBL20203510

Cc1nc(N)ccc1N1CCN(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.49
ADRA2C P18825 1/20 0.49
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
RAD52 P43351 1/20 0.47
ALDH1A1 P00352 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HRH4 Q9H3N8 7/20 0.46
HRH3 Q9Y5N1 2/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.45
PTK2B Q14289 1/20 0.45
HTR3A P46098 1/20 0.44
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29814673 1.00 NCF1 (0.49) NCF1ADRA2CKDM4EMAPTPOLB
SCHEMBL18823165 0.82 HTR3B (0.53) NCF1ADRA2CKDM4EMAPTPOLB
SCHEMBL23106921 0.81 HTR3A (0.53) NCF1ADRA2CKDM4EMAPTPOLB
SCHEMBL2490090 0.81 HRH3 (0.41) KDM4EMAPTALDH1A1HRH4HRH3
SCHEMBL21698629 0.81 GAA (0.55) KDM4EMAPTPOLBRAD52ALDH1A1
SCHEMBL22112920 0.81 NOS3 (0.40) NCF1KDM4EMAPTALDH1A1GAA
SCHEMBL18291344 0.81 NCF1 (0.48) NCF1HRH4HRH3HTR3ANOS3
SCHEMBL21698767 0.81 NCF1 (0.48) NCF1KDM4EMAPTPOLBALDH1A1
SCHEMBL20918330 0.78 HRH4 (0.48) NCF1ADRA2CKDM4EMAPTPOLB
SCHEMBL20203393 0.76 CDK4 (0.43) NCF1ADRA2CKDM4EMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-11548890-B1 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2023-01-10 US disclosed
US-11548890-B1 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2023-01-10 US disclosed
US-20220315584-A1 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2022-10-06 US disclosed
CN-114945366-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2022-08-26 CN disclosed
EP-4027995-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-07-20 EP disclosed
US-20210078996-A1 HPK1 ANTAGONISTS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
US-20210078996-A1 HPK1 ANTAGONISTS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
US-20210078997-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
EP-3546458-B1 ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER TEIJIN PHARMA LTD (JP) 2021-01-06 EP disclosed
US-20200270251-A1 IMIDAZO[1',2':1,6]PYRIDO[2,3-D]PYRIMIDINE COMPOUND AS PROTEIN KINASE INHIBITOR SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2020-08-27 US disclosed
EP-3608321-A1 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) 2020-02-12 EP disclosed
EP-3546458-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Teijin Pharma Limited (JP) 2019-10-02 EP disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315584-A1 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR CDK4, CDK2, CDKL1 NCF1 1401/4885ADRA2C 4139/4885KDM4E 784/4885
US-11548890-B1 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 NCF1 2432/4885ADRA2C 4322/4885KDM4E 3143/4885
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS HIPK1, PDXK, IP6K1 NCF1 2242/4885ADRA2C 1014/4885KDM4E 3589/4885
US-20200270251-A1 IMIDAZO[1',2':1,6]PYRIDO[2,3-D]PYRIMIDINE COMPOUND AS PROTEIN KINASE INHIBITOR CDK2, CDK4, CDK1 NCF1 1578/4885ADRA2C 4214/4885KDM4E 1305/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 NCF1 2432/4885ADRA2C 4322/4885KDM4E 3143/4885
US-20210078997-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS HIPK1, PDXK, IP6K1 NCF1 2035/4885ADRA2C 1054/4885KDM4E 3754/4885
US-20210078996-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 NCF1 2432/4885ADRA2C 4322/4885KDM4E 3143/4885
US-12215105-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 NCF1 2432/4885ADRA2C 4322/4885KDM4E 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.